Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice

Vaccine

Volumn 32, Issue 34, 2014, Pages 4281-4288

  Feunou, Pascal F ^a,b,c   Kammoun, Hana ^a,b,c   Debrie, Anne Sophie ^a,b,c   Locht, Camille ^a,b,c  

^a Institut Pasteur de Lille Center for Infection and Immunity of Lille ^*

^b INSERM U1019   (France)

^c UNIV LILLE   (France)

Author keywords

Pertussis; Prime boost; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; BORDETELLA PERTUSSIS ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 5; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; CYTOKINE; IMMUNOGLOBULIN G; LIVE VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; INFANT; MOUSE; NEWBORN; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN CELL; TH17 CELL; TH2 CELL; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; CLASSIFICATION; FEMALE; IMMUNIZATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; TH1 CELL; WHOOPING COUGH;

ADMINISTRATION, INTRANASAL; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BORDETELLA PERTUSSIS; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MICE, INBRED BALB C; PERTUSSIS VACCINE; TH1 CELLS; TH17 CELLS; VACCINES, ATTENUATED; WHOOPING COUGH;

EID: 84903818388     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.019     Document Type: Article

References (44)

1. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984, 8369:122-126.
2. Decker M.D., Edwards K.M. Acellular pertussis vaccines. Pediatr Clin North Am 2000, 47:309-335.
3. Von König C.H., Halperin S., Riffelmann M., Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002, 2:744-750.
4. Crowcroft N.S., Stein C., Duclos P., Birmingham M. How best to estimate the global burden of pertussis. Lancet Infect Dis 2003, 3:423-428.
5. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005, 24(Suppl):S104-S108.
6. Cherry J.D. Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease. N Engl J Med 2012, 367:785-787.
7. Clark T.A., Messonnier N.E., Hadler S.C. Pertussis control: time for something new. Trends Microbiol 2012, 20:211-213.
8. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct Th cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998, 93:1-10.
9. Ausiello C.M., Urbani F., la Sala A., Lande R., Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 1997, 93:2168-2174.
10. Mascart F., Hainaut M., Peltier A., Verscheure V., Levy J., Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007, 25:391-398.
11. Rowe J., Macaubas C., Monger T.M., Holt B.J., Harvey J., Poolman J.T., et al. Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infect Immun 2000, 68:3873-3877.
12. Farooqi I.S., Hopkin J.M. Early childhood infection and atopic disorder. Thorax 1998, 53:927-932.
13. Rowe J., Macaubas C., Monger T., Holt B.J., Harvey J., Poolman J.T., et al. Heterogeneity in diphtheria-tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Th1 function. J Infect Dis 2001, 184:80-88.
14. Holt P.G., Clough J.B., Holt B.J., Baron-Hay M.J., Rose A.H., Robinson R.W., et al. Genetic risk for atopy is associated with delayed postnatal maturation of T-cell competence. Clin Exp Allergy 1992, 22:1093-1099.
15. Holt P.G., Rubin A., Macaubas C., Holt B.J., Rowe J., Loh R., et al. Development of immunological memory against tetanus toxoid and pertactin antigens from the diphtheria-tetanus-pertussis vaccine in atopic versus nonatopic children. J Allergy Clin Immunol 2000, 105:1117-1122.
16. Van der Velden V.H., Laan M.P., Baert M.R., de Waal Malefyt R., Neijens H.J., Savelkoul H.F. Selective development of a strong Th2 cytokine profile in high-risk children who develop atopy: risk factors and regulatory role of IFN-gamma, IL-4 and IL-10. Clin Exp Allergy 2001, 31:997-1006.
17. Decker M.D., Edwards K.M., Steinhoff M.C., Rennels M.B., Pichichero M.E., Englund J., et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995, 96:557-566.
18. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54:1730-1735.
19. Wearing H.J., Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog 2009, 5:e1000647.
20. Mascart F., Verscheure V., Malfroot A., Hainaut M., Piérard D., Temerman S., et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 2003, 170:1504-1509.
21. Mielcarek N., Debrie A.S., Raze D., Bertout J., Rouanet C., Younes A.B., et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006, 2:e65.
22. Thorstensson R., Trollflors B., Al-Tawil N., Jahnmatz M., Bergström J., Ljungman M., et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine-BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One 2013, 9:e83449.
23. Feunou F.P., Ismaili J., Debrie A.S., Huot L., Hot D., Raze D., et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 2008, 26:5722-5727.
24. Feunou P.F., Bertout J., Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS One 2010, 5:e10178.
25. Feunou P.F., Kammoun H., Debrie A.S., Mielcarek N., Locht C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 2010, 28:7047-7053.
26. Skerry C.M., Mahon B.P. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol 2011, 18:187-193.
27. Menozzi F.D., Mutombo R., Renauld G., Gantiez C., Hannah J.H., Leininger E., et al. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect Immun 1994, 62:769-778.
28. Antoine R., Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun 1990, 58:1518-1526.
29. Locht C., Geoffroy M.C., Renauld G. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbrae share sequence similarities with the papC and papD gene families. EMBO J 1992, 11:3175-3183.
30. Hijnen M., Van Gageldonk P.G., Berbers G.A., Van Woerkom T., Mooi F.R. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif 2005, 41:106-112.
31. Mills K.H.G., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998, 66:594-602.
32. Mielcarek N., Debrie A.S., Mahieux S., Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol 2010, 17:317-324.
33. Paddock C.D., Sanden G.N., Cherry J.D., Gal A.A., Lanston C., Tatti K.M., et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 2008, 47:328-338.
34. Locht C., Mielcarek N. New pertussis vaccination approaches: en route to protect newborns. FEMS Immunol Med Microbiol 2012, 66:121-133.
35. Locht C. A common vaccination strategy to solve unsolved problems of tuberculosis and pertussis. Microb Infect 2008, 10:1051-1056.
36. Mills K.H.G., Barnard A., Watkins J., Redhead K. Cell mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993, 61:399-410.
37. Higgins S.C., Jarnicki A.G., Lavelle E.D., Mills K.H.G. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006, 177:7980-7989.
38. Ross P.J., Sutton C.E., Higgins S., Allen A.C., Walsh K., Misiak A., et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis. Towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 2013, e1003264.
39. Sutherland J.N., Chang C., Yoder S.M., Rock R., Maynard J.A. Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization. Clin Vaccine Immunol 2011, 18:954-962.
40. Ibsen P.H. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 1996, 14:359-368.
41. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24:S58-S61.
42. Rowe J., Yerkovich S.T., Richmond P., Suriyaarachchi D., Fischer E., Feddema L., et al. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children. Infect Immun 2005, 73:8130-8135.
43. Moghaddam A., Olszwska W., Wang B., Tregoning J.S., Helson R., Sattentau Q.J., et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006, 12:905-907.
44. Cherry J.D., Heininger U., Richards D.M., Storsaeter J., Gustafsson L., Ljungman M., et al. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol 2010, 17:741-747.